Results 31 to 40 of about 5,803 (182)

Prognosis Following Sustained Virologic Response in Korean Chronic Hepatitis C Patients Treated with Sofosbuvir-Based Treatment: Data from a Multicenter Prospective Observational Study up to 7 Years

Medicina
Background and Objectives: Chronic hepatitis C (CHC) can be cured with direct-acting antiviral (DAA) therapy. In Korea, sofosbuvir (SOF) and ledipasvir (LDV)/SOF were launched in 2016.
Yewan Park, Seong-Kyun Na, Jae-Hyun Yoon, Sung-Eun Kim, Ji-Won Park, Gi-Ae Kim, Hyo-Young Lee, Young-Sun Lee, Jeong-Han Kim   +8 more
doaj   +1 more source

Absence of progressive liver disease after treatment in children with chronic hepatitis C: A nationwide registry study

Journal of Pediatric Gastroenterology and Nutrition, EarlyView.
Abstract Objectives In adults with chronic hepatitis C (CHC) and advanced fibrosis, hepatocellular carcinoma (HCC) surveillance is recommended after achieving a sustained virologic response (SVR). However, post‐SVR surveillance strategies for children remain unclear. The aim of this study was to assess the durability of SVR and determine an appropriate
Hitoshi Tajiri, Mitsuyoshi Suzuki, Yuri Etani, Yoshinori Ito, Koichi Ito, Tomoya Fukuoka, Tatsuki Mizuochi   +6 more
wiley   +1 more source

Should they wait? Two children under 3 years old infected by HCV 1b successfully treated by ledipasvir/sofosbuvir: A report of two cases

Liver Research, 2023
Although direct-acting antivirals (DAAs) have notably increased the sustained virological response (SVR) rates in hepatitis C virus (HCV)-infected adolescent patients, the efficacy and safety for young children under 3 years old remain unclear. Currently,
Mingna Li, Kuerbannisa Wulayin, Shutao Lin, Chao Wu, Lubiao Chen   +4 more
doaj   +1 more source

Pooled risk ratio of sustained virological response at week 12 after the end of treatment between sofosbuvir plus ledipasvir with ribavirin and sofosbuvir plus ledipasvir.

, 2018
Pooled risk ratio of sustained virological response at week 12 after the end of treatment between sofosbuvir plus ledipasvir with ribavirin and sofosbuvir plus ledipasvir.
Thunyarat Anothaisintawee (840641), Yot Teerawattananon (180232), Ammarin Thakkinstian (840643), Thanthima Suwanthawornkul (840640), Abhasnee Sobhonslidsuk (840642)   +4 more
core   +1 more source

Serum Agalactosyl IgG Predicts Hepatocellular Carcinoma and All‐Cause Mortality After SVR in Advanced Chronic Hepatitis C

Hepatology Research, EarlyView.
ABSTRACT Background and Aims Patients with chronic hepatitis C and advanced fibrosis remain at substantial risk of hepatocellular carcinoma (HCC) and non‐liver–related death even after sustained virological response (SVR) to direct‐acting antivirals (DAA).
Daisuke Sakon, Jumpei Kondo, Yuki Tahata, Hayato Hikita, Maki Iwaisako, Muya Matsumoto, Asuka Ogata, Shinji Takamatsu, Yasutoshi Nozaki, Naruyasu Kakita, Hisashi Ishida, Fumihiko Nakanishi, Yuichi Yoshida, Masanori Nakahara, Kazuho Imanaka, Mitsuru Sakakibara, Takayuki Yakushijin, Tetsuo Takehara, Takahiro Kodama, Eiji Miyoshi   +19 more
wiley   +1 more source

Direct Acting Antiviral Agents in Korean Patients with Chronic Hepatitis C and Hemophilia Who Are Treatment-Naïve or Treatment-Experienced

Gut and Liver, 2017
Background/AimsChronic hepatitis C (CHC) is a major comorbidity in patients with hemophilia.Methods : Patients (n=30) were enrolled between September 2015 and April 2016.
Hyun Woong Lee, Ki Young Yoo, Joung Won Won, Hyung Joon Kim   +3 more
doaj   +1 more source

The impact of public coverage of newer hepatitis C medications on utilization, adherence, and costs in British Columbia.

PLoS ONE, 2021
BackgroundSofosbuvir and ledipasvir-sofosbuvir are both newer direct-acting antiviral agents for the treatment of hepatitis C. The high list prices for both drugs have led to concern about the budget impact for public drug coverage programs.
Harriet Ho, Naveed Z Janjua, Kimberlyn M McGrail, Mark Harrison, BC Hepatitis Testers Cohort Team, Michael R Law   +5 more
doaj   +1 more source

Development of a Machine Learning Model to Predict Short Duration HCV Treatment Response

Journal of Viral Hepatitis, Volume 33, Issue 10, October 2026.
ABSTRACT Standard durations of direct acting antivirals (DAAs; 8–12 weeks) can be a barrier to HCV treatment initiation and completion among marginalized populations. This study developed and internally validated a machine learning model to predict short‐duration (4–6 weeks) DAA response using baseline clinical factors with potential to improve ...
Joanne M. Carson, Sebastiano Barbieri, Andrey Verich, Elise Tu, Andrew Lloyd, Gregory J. Dore, Gail V. Matthews, Marianne Martinello   +7 more
wiley   +1 more source

Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis

, 2014
BACKGROUND High rates of sustained virologic response were observed among patients with hepatitis C virus (HCV) infection who received 12 weeks of treatment with the nucleotide polymerase inhibitor sofosbuvir combined with the NS5A inhibitor ledipasvir ...
Reddy, K. R., Shiffman, M. L., Schiff, E., Ghalib, R., Kowdley, K. V., Gordon, S. C., Rossaro, L., Bernstein, D. E., Lawitz, E., Fried, M. W., +15 additional authors   +10 more
core   +1 more source

Sex Disparities in Hepatitis C Treatment Initiation: Role of Universal Access to DAA in France (ANRS FANTASIO 2)

Liver International, Volume 46, Issue 10, October 2026.
ABSTRACT Background and Aims Ensuring access to direct‐acting antivirals (DAA) for all individuals concerned is a priority in hepatitis C elimination efforts. We analysed sex disparities in DAA initiation in France over a 9‐year period spanning before and after August 2017, when the country implemented universal DAA access.
Fabienne Marcellin, Clémence Ramier, Cécile Brouard, Vincent Di Beo, Yoann Allier, Abbas Mourad, Morgane Bureau‐Stoltmann, Philippe Sogni, Sylvie Deuffic‐Burban, Patrizia Carrieri, Benjamin Rolland, Marc Bourliere, Camelia Protopopescu   +12 more
wiley   +1 more source